US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ERShares Entrepreneurs ETF

15.31

0.0000

Volume:- -

Turnover:4.92K

Market Cap:84.21M

PE:- -

High:15.31

Open:15.31

Low:15.31

Close:15.31

52wk High:16.00

52wk Low:10.72

Shares:5.50M

Float Shares:5.50M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:0.48

PE(LYR):- -

Loading ...

Overview Company News Filings

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

Entrada Therapeutics Says FDA Lifted Clinical Hold on ENTR-601-44; Shares Advance Premarket

MT Newswires Live

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ENTR/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ENTR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ENTR\",,,,,undefined,":{"symbol":"ENTR","market":"US","secType":"STK","nameCN":"ERShares Entrepreneurs ETF","latestPrice":15.31,"timestamp":1724875200000,"preClose":15.31,"halted":8,"volume":0,"delay":0,"changeRate":0,"floatShares":5500000,"shares":5500000,"eps":0,"marketStatus":"Market Closed","change":0,"latestTime":"08-28 16:00:00 EDT","open":15.31,"high":15.31,"low":15.31,"amount":4922.4664,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771318800000},"marketStatusCode":7,"symbolChange":{"newSymbol":"XOVR","executeDate":"2024-08-29"},"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":15.31,"sharesOutstanding":5500000,"nav":15.28,"aum":312010163.4,"bidAskSpread":0,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ENTR\",,,,,undefined,":{"symbol":"ENTR","floatShares":5500000,"roa":"--","roe":"--","lyrEps":0,"shares":5500000,"dividePrice":0,"high":15.31,"amplitude":0,"preClose":15.31,"low":15.31,"week52Low":10.72,"pbRate":"0.48","week52High":16,"institutionHeld":0,"latestPrice":15.31,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":15.31},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ENTR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-08-29","symbol":"ENTR","oldSymbol":"ENTR","defaultRemindTime":1724938200000,"newSymbol":"XOVR","exchange":"NYSE","type":"symbolChange","dateTimestamp":1724904000000},{"market":"US","date":"2021-12-21","symbol":"ENTR","amount":3.9863,"defaultRemindTime":1640097000000,"name":"熵通科技","recordDate":"2021-12-28","payableDate":"2021-12-22","currency":"USD","type":"dividend","dateTimestamp":1640062800000},{"market":"US","date":"2020-12-21","symbol":"ENTR","amount":0.911823,"defaultRemindTime":1608561000000,"name":"熵通科技","payableDate":"2020-12-22","currency":"USD","type":"dividend","dateTimestamp":1608526800000},{"market":"US","date":"2019-12-19","symbol":"ENTR","amount":0.014354,"name":"熵通科技","payableDate":"2019-12-20","currency":"USD","type":"dividend","dateTimestamp":1576731600000},{"market":"US","date":"2018-12-18","symbol":"ENTR","amount":0.000729,"name":"熵通科技","currency":"USD","type":"dividend","dateTimestamp":1545109200000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ENTR\",market:\"US\",,,undefined,":[{"executeDate":"2018-12-18","recordDate":null,"paymentDate":null,"value":0.000729,"currency":"USD"},{"executeDate":"2019-12-19","recordDate":"2019-12-20","paymentDate":null,"value":0.014354,"currency":"USD"},{"executeDate":"2020-12-21","recordDate":"2020-12-22","paymentDate":null,"value":0.911823,"currency":"USD"},{"executeDate":"2021-12-21","recordDate":"2021-12-22","paymentDate":"2021-12-28","value":3.9863,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ENTR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ENTR\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2521759746","title":"Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping","url":"https://stock-news.laohu8.com/highlight/detail?id=2521759746","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521759746?lang=en_us&edition=fundamental","pubTime":"2025-03-24 19:00","pubTimestamp":1742814000,"startTime":"0","endTime":"0","summary":"– Company on track to initiate ELEVATE-45-201 study in Q3 2025 – – ELEVATE-45 regulatory filings submitted in the EU, with regulatory review ongoing – – ELEVATE-45 is the second of three novel exon sk","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/24/3047704/0/en/Entrada-Therapeutics-Receives-Authorization-in-the-United-Kingdom-to-Initiate-ELEVATE-45-201-a-Phase-1-2-Multiple-Ascending-Dose-Clinical-Study-of-ENTR-601-45-in-People-Living-with.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4211","TRDA","ENTR","PMO","BK4139","UBCP"],"gpt_icon":0},{"id":"2513253937","title":"Entrada Therapeutics Says FDA Lifted Clinical Hold on ENTR-601-44; Shares Advance Premarket","url":"https://stock-news.laohu8.com/highlight/detail?id=2513253937","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513253937?lang=en_us&edition=fundamental","pubTime":"2025-02-24 20:43","pubTimestamp":1740401006,"startTime":"0","endTime":"0","summary":"Entrada Therapeutics  said Monday that the US Food and Drug Administration has lifted the clinical hold on ENTR-601-44 and cleared the company's plan to start a phase 1b study of the product candidate as a potential treatment for adults with Duchenne muscular dystrophy or DMD.The company said the 1b study is designed to evaluate ENTR-601-44's safety and tolerability in about 32 adults with DMD who are exon-44 skipping amenable.Shares of Entrada Therapeutics were up more than 9% in recent premarket activity Monday.Price: 14.28, Change: +1.24, Percent Change: +9.51","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ENTR","TRDA","LENZ"],"gpt_icon":0},{"id":"2508128121","title":"Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2508128121","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508128121?lang=en_us&edition=fundamental","pubTime":"2025-02-03 20:00","pubTimestamp":1738584000,"startTime":"0","endTime":"0","summary":"– Company on track to initiate ELEVATE-44-201 in Q2 2025 – – ENTR-601-44 regulatory filings submitted in additional geographies including the U.S. and EU, with regulatory discussions ongoing – BOSTON,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/03/3019369/0/en/Entrada-Therapeutics-Receives-Authorization-in-the-United-Kingdom-to-Initiate-ELEVATE-44-201-a-Phase-1-2-Multiple-Ascending-Dose-Clinical-Study-of-ENTR-601-44-in-Patients-Living-wi.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","ENTR","PMO","UBCP","BK4211","BK4139","TRDA"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}]}}